Research progress and prospects of neoadjuvant endocrine therapy for breast cancer

Yao QIAN; Feng LIU

doi:10.19401/j.cnki.1007-3639.2022.07.008

您当前的位置：

首页 >

文章列表页 >

Research progress and prospects of neoadjuvant endocrine therapy for breast cancer

Review | 更新时间：2025-12-31

- Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
- China Oncology Vol. 32, Issue 7, Pages: 643-649(2022)
- 作者机构：
  
  哈尔滨医科大学附属肿瘤医院乳腺外科,黑龙江哈尔滨 150081
- 作者简介：
  
  LIU Feng, E-mail: fengliu101@hotmail.com.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.07.008
  CLC： R737.9
- Received：04 April 2022，
  
  Published：30 July 2022
- 稿件说明：
移动端阅览
Yao QIAN, Feng LIU. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer[J]. China Oncology, 2022, 32(7): 643-649.
DOI：

Yao QIAN, Feng LIU. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer[J]. China Oncology, 2022, 32(7): 643-649. DOI： 10.19401/j.cnki.1007-3639.2022.07.008.

摘要

新辅助内分泌治疗（neoadjuvant endocrine therapy

NET）代替新辅助化疗（neoadjuvant chemotherapy therapy

NCT）对于雌激素受体（estrogen receptor

ER）阳性乳腺癌患者而言是一种有效的临床治疗策略

可以使肿瘤降期

从而接受乳腺癌保乳手术并减少术后的辅助化疗。本文旨在就NET的患者选择、NET效果对比、NET持续时间、NET与NCT效果对比及联合使用、NET联合靶向治疗、机会之窗试验、疗效评估预后指标及NET后辅助治疗决策等最新研究进展进行综述。

Abstract

Neoadjuvant endocrine therapy (NET) instead of neoadjuvant chemotherapy (NCT) is an effective clinical strategy for estrogen receptor (ER)-positive breast cancer patients

which can reduce tumor stage

achieve breast-conserving surgery for breast cancer and reduce the need for adjuvant chemotherapy. This article aimed to review the latest research progress in several aeras: patient selection for NET

comparison of efficacy of NET

duration of NET

comparison and combined use of NET and NCT

NET combined with targeted therapy

window of opportunity trials

efficacy evaluation indicators and adjuvant therapy decision after neoadjuvant endocrine therapy.

关键词

Keywords

references

SIEGEL R L , MILLER K D , GODING SAUER A , et al . Colorectal cancer statistics, 2020 [J ] . CA A Cancer J Clin , 2020 , 70 ( 3 ): 145 - 164 . DOI: 10.3322/caac.21601 http://doi.org/10.3322/caac.21601 https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21601 https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21601

CORTAZAR P , ZHANG L J , UNTCH M , et al . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J ] . Lancet , 2014 , 384 ( 9938 ): 164 - 172 . DOI: 10.1016/S0140-6736(13)62422-8 http://doi.org/10.1016/S0140-6736(13)62422-8 https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228 https://linkinghub.elsevier.com/retrieve/pii/S0140673613624228

BERRY D A , CIRRINCIONE C , HENDERSON I C , et al . Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J ] . JAMA , 2006 , 295 ( 14 ): 1658 - 1667 . DOI: 10.1001/jama.295.14.1658 http://doi.org/10.1001/jama.295.14.1658 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.14.1658 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.295.14.1658

GIANNI L , PIENKOWSKI T , IM Y H , et al . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial [J ] . Lancet Oncol , 2012 , 13 ( 1 ): 25 - 32 . DOI: 10.1016/S1470-2045(11)70336-9 http://doi.org/10.1016/S1470-2045(11)70336-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703369 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703369

SCHNEEWEISS A , CHIA S , HICKISH T , et al . Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA) [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2278 - 2284 . DOI: 10.1093/annonc/mdt182 http://doi.org/10.1093/annonc/mdt182 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369297

SIKOV W M , BERRY D A , PEROU C M , et al . Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance) [J ] . J Clin Oncol , 2015 , 33 ( 1 ): 13 - 21 .

CARDOSO F , KYRIAKIDES S , OHNO S , et al . Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2019 , 30 ( 8 ): 1194 - 1220 . DOI: 10.1093/annonc/mdz173 http://doi.org/10.1093/annonc/mdz173 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312876 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312876

GRADISHAR W J , ANDERSON B O , ABRAHAM J , et al . Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Cancer Netw , 2020 , 18 ( 4 ): 452 - 478 .

BURSTEIN H J , CURIGLIANO G , THÜRLIMANN B , et al . Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021 [J ] . Ann Oncol , 2021 , 32 ( 10 ): 1216 - 1235 . DOI: 10.1016/j.annonc.2021.06.023 http://doi.org/10.1016/j.annonc.2021.06.023 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049 https://linkinghub.elsevier.com/retrieve/pii/S0923753421021049

DOWSETT M , ELLIS M J , DIXON J M , et al . Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic [J ] . NPJ Breast Cancer , 2020 , 6 : 21 . DOI: 10.1038/s41523-020-0168-9 http://doi.org/10.1038/s41523-020-0168-9 https://doi.org/10.1038/s41523-020-0168-9 https://doi.org/10.1038/s41523-020-0168-9

NABHOLTZ J M , BUZDAR A , POLLAK M , et al . Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group [J ] . J Clin Oncol , 2000 , 18 ( 22 ): 3758 - 3767 . DOI: 10.1200/JCO.2000.18.22.3758 http://doi.org/10.1200/JCO.2000.18.22.3758 https://ascopubs.org/doi/10.1200/JCO.2000.18.22.3758 https://ascopubs.org/doi/10.1200/JCO.2000.18.22.3758

SMITH I E , DOWSETT M , EBBS S R , et al . Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial [J ] . J Clin Oncol , 2005 , 23 ( 22 ): 5108 - 5116 . DOI: 10.1200/JCO.2005.04.005 http://doi.org/10.1200/JCO.2005.04.005 https://ascopubs.org/doi/10.1200/JCO.2005.04.005 https://ascopubs.org/doi/10.1200/JCO.2005.04.005

CATALIOTTI L , BUZDAR A U , NOGUCHI S , et al . Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial [J ] . Cancer , 2006 , 106 ( 10 ): 2095 - 2103 . DOI: 10.1002/cncr.21872 http://doi.org/10.1002/cncr.21872 https://onlinelibrary.wiley.com/doi/10.1002/cncr.21872 https://onlinelibrary.wiley.com/doi/10.1002/cncr.21872

MASUDA N , SAGARA Y , KINOSHITA T , et al . Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial [J ] . Lancet Oncol , 2012 , 13 ( 4 ): 345 - 352 . DOI: 10.1016/S1470-2045(11)70373-4 http://doi.org/10.1016/S1470-2045(11)70373-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703734 https://linkinghub.elsevier.com/retrieve/pii/S1470204511703734

EIERMANN W , PAEPKE S , APPFELSTAEDT J , et al . Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study [J ] . Ann Oncol , 2001 , 12 ( 11 ): 1527 - 1532 . DOI: 10.1023/A:1013128213451 http://doi.org/10.1023/A:1013128213451 https://linkinghub.elsevier.com/retrieve/pii/S0923753419543794 https://linkinghub.elsevier.com/retrieve/pii/S0923753419543794

SEMIGLAZOV V , KLETSEL A , SEMIGLAZOV V , et al . Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) [J ] . J Clin Oncol , 2005 , 23 (16_suppl): 530 . DOI: 10.1200/jco.2005.23.16_suppl.530 http://doi.org/10.1200/jco.2005.23.16_suppl.530 http://ascopubs.org/doi/10.1200/jco.2005.23.16_suppl.530 http://ascopubs.org/doi/10.1200/jco.2005.23.16_suppl.530

ELLIS M J , SUMAN V J , HOOG J , et al . Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype: ACOSOG Z1031 [J ] . J Clin Oncol , 2011 , 29 ( 17 ): 2342 - 2349 . DOI: 10.1200/JCO.2010.31.6950 http://doi.org/10.1200/JCO.2010.31.6950 https://ascopubs.org/doi/10.1200/JCO.2010.31.6950 https://ascopubs.org/doi/10.1200/JCO.2010.31.6950

QUENEL-TUEUX N , DEBLED M , RUDEWICZ J , et al . Clinical and genomic analysis of a randomised phase Ⅱ study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer [J ] . Br J Cancer , 2015 , 113 ( 4 ): 585 - 594 . DOI: 10.1038/bjc.2015.247 http://doi.org/10.1038/bjc.2015.247 https://doi.org/10.1038/bjc.2015.247 https://doi.org/10.1038/bjc.2015.247

LEREBOURS F , RIVERA S , MOURET-REYNIER M A , et al . Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609) [J ] . Cancer , 2016 , 122 ( 19 ): 3032 - 3040 . DOI: 10.1002/cncr.30143 http://doi.org/10.1002/cncr.30143 https://onlinelibrary.wiley.com/doi/10.1002/cncr.30143 https://onlinelibrary.wiley.com/doi/10.1002/cncr.30143

MA C X , SUMAN V , LEITCH A M , et al . Abstract GS4-05: neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage Ⅱ or Ⅲ estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (alliance A011106) [C ] . American Association for Cancer Research , 2021 .

ALLEVI G , STRINA C , ANDREIS D , et al . Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer [J ] . Br J Cancer , 2013 , 108 ( 8 ): 1587 - 1592 . DOI: 10.1038/bjc.2013.151 http://doi.org/10.1038/bjc.2013.151 https://doi.org/10.1038/bjc.2013.151 https://doi.org/10.1038/bjc.2013.151

CARPENTER R , DOUGHTY J C , CORDINER C , et al . Optimum duration of neoadjuvant letrozole to permit breast conserving surgery [J ] . Breast Cancer Res Treat , 2014 , 144 ( 3 ): 569 - 576 . DOI: 10.1007/s10549-014-2835-8 http://doi.org/10.1007/s10549-014-2835-8 http://link.springer.com/10.1007/s10549-014-2835-8 http://link.springer.com/10.1007/s10549-014-2835-8

FONTEIN D B , CHAREHBILI A , NORTIER J W , et al . Efficacy of six months neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients: a phase Ⅱ trial [J ] . Eur J Cancer , 2014 , 50 ( 13 ): 2190 - 2200 . DOI: 10.1016/j.ejca.2014.05.010 http://doi.org/10.1016/j.ejca.2014.05.010 https://linkinghub.elsevier.com/retrieve/pii/S0959804914006601 https://linkinghub.elsevier.com/retrieve/pii/S0959804914006601

DIXON J M , RENSHAW L , MACASKILL E J , et al . Increase in response rate by prolonged treatment with neoadjuvant letrozole [J ] . Breast Cancer Res Treat , 2009 , 113 ( 1 ): 145 - 151 . DOI: 10.1007/s10549-008-9915-6 http://doi.org/10.1007/s10549-008-9915-6 http://link.springer.com/10.1007/s10549-008-9915-6 http://link.springer.com/10.1007/s10549-008-9915-6

SEMIGLAZOV V F , SEMIGLAZOV V V , DASHYAN G A , et al . Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer [J ] . Cancer , 2007 , 110 ( 2 ): 244 - 254 . DOI: 10.1002/cncr.22789 http://doi.org/10.1002/cncr.22789 https://onlinelibrary.wiley.com/doi/10.1002/cncr.22789 https://onlinelibrary.wiley.com/doi/10.1002/cncr.22789

ALBA E , CALVO L , ALBANELL J , et al . Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-Ⅱ study [J ] . Ann Oncol , 2012 , 23 ( 12 ): 3069 - 3074 . DOI: 10.1093/annonc/mds132 http://doi.org/10.1093/annonc/mds132 https://linkinghub.elsevier.com/retrieve/pii/S0923753419374708 https://linkinghub.elsevier.com/retrieve/pii/S0923753419374708

SPRING L M , GUPTA A , REYNOLDS K L , et al . Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis [J ] . JAMA Oncol , 2016 , 2 ( 11 ): 1477 - 1486 . DOI: 10.1001/jamaoncol.2016.1897 http://doi.org/10.1001/jamaoncol.2016.1897 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1897 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1897

WANG Y L , HE L , SONG Y H , et al . The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis [J ] . BMC Womens Health , 2020 , 20 ( 1 ): 17 . DOI: 10.1186/s12905-020-0879-y http://doi.org/10.1186/s12905-020-0879-y https://doi.org/10.1186/s12905-020-0879-y https://doi.org/10.1186/s12905-020-0879-y

GRADISHAR W J , MORAN M S , ABRAHAM J , et al . NCCN guidelines ® insights: breast cancer, version 4.2021 [J ] . J Natl Compr Canc Netw , 2021 , 19 ( 5 ): 484 - 493 . DOI: 10.6004/jnccn.2021.0023 http://doi.org/10.6004/jnccn.2021.0023 https://jnccn.org/view/journals/jnccn/19/5/article-p484.xml https://jnccn.org/view/journals/jnccn/19/5/article-p484.xml

SATO N , MASUDA N , MORIMOTO T , et al . Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks’ exemestane exposure in patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase Ⅱ study [J ] . Cancer Med , 2019 , 8 ( 12 ): 5468 - 5481 . DOI: 10.1002/cam4.2423 http://doi.org/10.1002/cam4.2423 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2423 https://onlinelibrary.wiley.com/doi/10.1002/cam4.2423

MATSUNUMA R , WATANABE T , HOZUMI Y , et al . Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer [J ] . Breast Cancer , 2020 , 27 ( 5 ): 819 - 827 . DOI: 10.1007/s12282-020-01077-0 http://doi.org/10.1007/s12282-020-01077-0 https://doi.org/10.1007/s12282-020-01077-0 https://doi.org/10.1007/s12282-020-01077-0

SPRING L M , WANDER S A , ANDRE F , et al . Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future [J ] . Lancet , 2020 , 395 ( 10226 ): 817 - 827 . DOI: 10.1016/S0140-6736(20)30165-3 http://doi.org/10.1016/S0140-6736(20)30165-3 https://linkinghub.elsevier.com/retrieve/pii/S0140673620301653 https://linkinghub.elsevier.com/retrieve/pii/S0140673620301653

MA C X , GAO F , LUO J Q , et al . NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer [J ] . Clin Cancer Res , 2017 , 23 ( 15 ): 4055 - 4065 . DOI: 10.1158/1078-0432.CCR-16-3206 http://doi.org/10.1158/1078-0432.CCR-16-3206 https://aacrjournals.org/clincancerres/article/23/15/4055/256945/NeoPalAna-Neoadjuvant-Palbociclib-a-Cyclin https://aacrjournals.org/clincancerres/article/23/15/4055/256945/NeoPalAna-Neoadjuvant-Palbociclib-a-Cyclin

HURVITZ S A , MARTIN M , PRESS M F , et al . Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase Ⅱ neoadjuvant study in HR+/HER2- breast cancer [J ] . Clin Cancer Res , 2020 , 26 ( 3 ): 566 - 580 . DOI: 10.1158/1078-0432.CCR-19-1425 http://doi.org/10.1158/1078-0432.CCR-19-1425 https://aacrjournals.org/clincancerres/article/26/3/566/83167/Potent-Cell-Cycle-Inhibition-and-Upregulation-of https://aacrjournals.org/clincancerres/article/26/3/566/83167/Potent-Cell-Cycle-Inhibition-and-Upregulation-of

COTTU P , D’HONDT V , DUREAU S , et al . Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer [J ] . Ann Oncol , 2018 , 29 ( 12 ): 2334 - 2340 . DOI: 10.1093/annonc/mdy448 http://doi.org/10.1093/annonc/mdy448 https://linkinghub.elsevier.com/retrieve/pii/S0923753419342358 https://linkinghub.elsevier.com/retrieve/pii/S0923753419342358

JOHNSTON S , PUHALLA S , WHEATLEY D , et al . Randomized phase Ⅱ study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial [J ] . J Clin Oncol , 2019 , 37 ( 3 ): 178 - 189 .

MILLER T W , REXER B N , GARRETT J T , et al . Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer [J ] . Breast Cancer Res , 2011 , 13 ( 6 ): 224 . DOI: 10.1186/bcr3039 http://doi.org/10.1186/bcr3039 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3039 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3039

SAURA C , HLAUSCHEK D , OLIVEIRA M , et al . Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J ] . Lancet Oncol , 2019 , 20 ( 9 ): 1226 - 1238 . DOI: 10.1016/S1470-2045(19)30334-1 http://doi.org/10.1016/S1470-2045(19)30334-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303341 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303341

BASELGA J , SEMIGLAZOV V , VAN DAM P , et al . Phase Ⅱ randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer [J ] . J Clin Oncol , 2009 , 27 ( 16 ): 2630 - 2637 . DOI: 10.1200/JCO.2008.18.8391 http://doi.org/10.1200/JCO.2008.18.8391 https://ascopubs.org/doi/10.1200/JCO.2008.18.8391 https://ascopubs.org/doi/10.1200/JCO.2008.18.8391

ARNEDOS M , ROULLEAUX DUGAGE M , PEREZ-GARCIA J , et al . Window of opportunity trials for biomarker discovery in breast cancer [J ] . Curr Opin Oncol , 2019 , 31 ( 6 ): 486 - 492 . DOI: 10.1097/CCO.0000000000000583 http://doi.org/10.1097/CCO.0000000000000583 https://journals.lww.com/10.1097/CCO.0000000000000583 https://journals.lww.com/10.1097/CCO.0000000000000583

SERRANO D , LAZZERONI M , GANDINI S , et al . A randomized phase Ⅱ presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer [J ] . Breast Cancer Res , 2013 , 15 ( 3 ): R47 . DOI: 10.1186/bcr3439 http://doi.org/10.1186/bcr3439 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3439 http://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3439

COHEN A L , FACTOR R E , MOONEY K , et al . POWERPIINC (preoperative window of endocrine therapy provides information to increase compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen [J ] . Breast , 2017 , 31 : 219 - 223 . DOI: 10.1016/j.breast.2016.11.016 http://doi.org/10.1016/j.breast.2016.11.016 https://linkinghub.elsevier.com/retrieve/pii/S0960977616302508 https://linkinghub.elsevier.com/retrieve/pii/S0960977616302508

CROSHAW R , SHAPIRO-WRIGHT H , SVENSSON E , et al . Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients [J ] . Ann Surg Oncol , 2011 , 18 ( 11 ): 3160 - 3163 . DOI: 10.1245/s10434-011-1919-5 http://doi.org/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5 http://link.springer.com/10.1245/s10434-011-1919-5

SYMMANS W F , PEINTINGER F , HATZIS C , et al . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy [J ] . J Clin Oncol , 2007 , 25 ( 28 ): 4414 - 4422 . DOI: 10.1200/JCO.2007.10.6823 http://doi.org/10.1200/JCO.2007.10.6823 https://ascopubs.org/doi/10.1200/JCO.2007.10.6823 https://ascopubs.org/doi/10.1200/JCO.2007.10.6823

NIELSEN T O , LEUNG S C Y , RIMM D L , et al . Assessment of Ki-67 in breast cancer: updated recommendations from the international Ki-67 in breast cancer working group [J ] . J Natl Cancer Inst , 2020 , 113 ( 7 ): 808 - 819 . DOI: 10.1093/jnci/djaa201 http://doi.org/10.1093/jnci/djaa201 https://academic.oup.com/jnci/article/113/7/808/6053794 https://academic.oup.com/jnci/article/113/7/808/6053794

ELLIS M J , TAO Y , LUO J Q , et al . Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics [J ] . J Natl Cancer Inst , 2008 , 100 ( 19 ): 1380 - 1388 . DOI: 10.1093/jnci/djn309 http://doi.org/10.1093/jnci/djn309 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djn309 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djn309

STAFFORD A , WILLIAMS A , EDMISTON K , et al . Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis [J ] . Ann Surg Oncol , 2020 , 27 ( 12 ): 4669 - 4677 . DOI: 10.1245/s10434-020-08905-9 http://doi.org/10.1245/s10434-020-08905-9 https://doi.org/10.1245/s10434-020-08905-9 https://doi.org/10.1245/s10434-020-08905-9

WEISS A , WONG S , GOLSHAN M , et al . Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach [J ] . Ann Surg Oncol , 2019 , 26 ( 13 ): 4326 - 4336 . DOI: 10.1245/s10434-019-07785-y http://doi.org/10.1245/s10434-019-07785-y https://doi.org/10.1245/s10434-019-07785-y https://doi.org/10.1245/s10434-019-07785-y

ELLIS M J , SUMAN V J , HOOG J , et al . Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (alliance) [J ] . J Clin Oncol , 2017 , 35 ( 10 ): 1061 - 1069 . DOI: 10.1200/JCO.2016.69.4406 http://doi.org/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406 https://ascopubs.org/doi/10.1200/JCO.2016.69.4406

KANTOR O , WONG S , WEISS A , et al . Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer [J ] . NPJ Breast Cancer , 2020 , 6 : 35 . DOI: 10.1038/s41523-020-00177-6 http://doi.org/10.1038/s41523-020-00177-6 https://doi.org/10.1038/s41523-020-00177-6 https://doi.org/10.1038/s41523-020-00177-6

SMITH I , ROBERTSON J , KILBURN L , et al . Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1443 - 1454 . DOI: 10.1016/S1470-2045(20)30458-7 http://doi.org/10.1016/S1470-2045(20)30458-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304587 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304587

HARBECK N , GLUZ O , KUEMMEL S , et al . Abstract GS4-04: endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), recurrence score <26 and Ki-67 response after preoperative endocrine therapy: primary outcome results from the WSG-ADAPT HR+/HER2- trial [C ] . American Association for Cancer Research , 2021 .

Views

1721

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on the association of breast cancer patients’ prognosis with internal mammary sentinel lymph node biopsy

Receptor discordance between primary breast cancer and liver metastases

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study

Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation

The role of TRIP6 in breast cancer and its mechanism

Related Author

Ruijie JIA

Zhiqiang SHI

Qi ZHANG

Yongjin LU

Junsheng ZHENG

Jing SUN

Zhao BI

Xiao SUN

Related Institution

Shandong First Medical University Affiliated Tumor Hospital (Shandong Provincial Institute of Cancer Prevention and Treatment, Shandong Cancer Hospital)

Shandong First Medical University (Shandong Provincial Academy of Medical Sciences)

Tianjin Medical University Cancer Institute and Hospital

Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰